The Company entered into a placement agency agreement, dated February 11, 2026 (the “Placement Agency Agreement”), with Rodman & Renshaw LLC (the “Placement Agent”), pursuant to which the Company eng…
we have obtained, among other things, a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing license from Regenerative to utilize or sublicense a certain method for culturing cells
The Company's product sales are generated from two product lines: ExoCR, sold to a single customer pursuant to a bill-and-hold arrangement as described below, and BioX, sold to multiple customers wit…
BioRestorative Therapies, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
BRTX-DEBT-8376
Warrants outstanding: 4495038
90%
xbrl warrant detail from xbrl 2025-12-31.
BRTX-DEBT
Debt stack $42,282
90%
Market cache reports total debt of $42,282.
BRTX-DEBT-8377
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
BioRestorative Therapies, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for BioRestorative Therapies, Inc..
BioRestorative Therapies, Inc. Ownership
Holder
Name
Confidence
Evidence
BRTX-OWNER-CITADEL-ADVISORS-LLC
Citadel Advisors Llc
90%
13F overlay lists Citadel Advisors Llc as top holder; 10 tracked holders.
BioRestorative Therapies, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
